Идёт набор NCT04664192

Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research

— Наблюдательное Respiratory Failure Interstitial Lung Disease Lung Diseases

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Patient Biospecimen Registry (observational and blood sampling).
Кому может быть актуально: Состояния в реестре: Respiratory Failure, Interstitial Lung Disease, Lung Diseases. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

A major goal of this protocol is to support biomarker studies in advanced lung diseases, lung transplantation care, and to improve our understanding of the effects of viral and other infectious exposures to outcomes in our lung transplant and ALD patient populations.

Подробное описание

The identification of biomarkers in a patient's blood or tissue that are specific for particular medical conditions (such as interstitial lung disease, chronic obstructive lung disease (COPD), and post-lung transplant rejection) is important for the prevention and early detection of the disease, as well as to advance our understanding of targeted therapies. Availability of biomarkers for diagnosis and for the prediction of patient prognosis and therapy promises personalized medicine. Patients may be selected based on the presence of particular gene mutations or circulating protein levels to receive personalized treatment. Furthermore, knowledge regarding genetic risk and susceptibility to infectious diseases as well as structural lung disease is rapidly growing-as whole genome sequencing and genome-wide association studies have become easier to do, genetic risk has emerged as increasingly important in understanding why and how some patients develop chronic lung disease. This is true for the spectrum of lung diseases treated in the ALD program, from those with airways diseases such as COPD to diffuse parenchymal lung diseases such as idiopathic pulmonary fibrosis (IPF). The availability of human biological specimens for research purposes is crucial for the advancement of medical knowledge of understanding, diagnosing, and treating chronic lung diseases and optimizing post-lung transplant care.

Вмешательства

Другое Patient Biospecimen Registry (observational and blood sampling)
Clinical data collected at every blood sample collection visit.

Первичные конечные точки

Diagnosis of patients with lung transplant [Срок оценки: 5 years]

Вторичные конечные точки (1)

Survival [Срок оценки: 5 years]

Критерии участия

Критерии включения

All individuals aged 18 years and older
Persons who have undergone lung transplantation at Baylor University Medical Center in the previous 10 years
Individual is able to understand and sign the informed consent form